Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Has Average Price Target of $21.00

Key Points

• Analysts remain broadly bullish: Amneal Pharmaceuticals has a “Moderate Buy” consensus from 10 brokers, with nine buys, one hold, and an average 12-month price target of $21.00.
• The stock opened at $19.77, near its 52-week high of $21.17, while the company reported quarterly EPS of $0.30—beating estimates of $0.24—on revenue of $796.2 million.
• Insiders sold shares worth approximately $7.2 million over the past 90 days, while institutional ownership stands at 31.82% following increased holdings from several major investment firms.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given an average rating of "Moderate Buy" by the ten brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.00.

Several equities analysts have recently weighed in on the company. Barclays boosted their target price on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Thursday, September 17th. Leerink Partners started coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $23.00 price target for the company. JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a $22.00 price objective on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Finally, Zacks Research downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 7th.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $19.77 on Friday. The firm has a market capitalization of $6.31 billion, a P/E ratio of 40.35, a price-to-earnings-growth ratio of 2.34 and a beta of 1.24. Amneal Pharmaceuticals has a 52 week low of $9.56 and a 52 week high of $21.17. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The company has a fifty day simple moving average of $18.07 and a two-hundred day simple moving average of $15.39.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Analysts anticipate that Amneal Pharmaceuticals will post 0.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the transaction, the director owned 210,252 shares in the company, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Nikita Shah sold 146,403 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at approximately $4,436,858.90. This represents a 36.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 413,016 shares of company stock valued at $7,216,567 in the last ninety days. 17.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its position in Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company's stock valued at $32,405,000 after acquiring an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Amneal Pharmaceuticals during the second quarter worth $17,573,000. Principal Financial Group Inc. boosted its stake in shares of Amneal Pharmaceuticals by 527.9% during the first quarter. Principal Financial Group Inc. now owns 972,529 shares of the company's stock valued at $12,089,000 after purchasing an additional 817,652 shares during the period. Quartz Partners LLC purchased a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at $5,559,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Amneal Pharmaceuticals by 107.7% in the fourth quarter. BNP Paribas Financial Markets now owns 703,664 shares of the company's stock worth $8,866,000 after purchasing an additional 364,801 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.